Korean study tracks Real-World safety of growth hormone treatment in children
NCT ID NCT05509894
Summary
This study monitors the safety and effectiveness of Ngenla growth hormone treatment in Korean children with growth hormone deficiency. Researchers will follow 565 children and adolescents aged 3 and older for up to 6 years during routine medical care. The study aims to track side effects and measure how well the treatment helps children grow taller over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC GROWTH HORMONE DEFICIENCY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.